Hoatlin:OHSU Knight Cancer Institute Advanced Topics in Cancer Biology: Difference between revisions
From OpenWetWare
Jump to navigationJump to search
| Line 134: | Line 134: | ||
| | | | ||
|-- | |-- | ||
| | |27-Apr | ||
| | |W. Fleming | ||
| | |Acute hematologic malignancies | ||
| | | | ||
|-- | |-- | ||
| | |29-Apr | ||
| | |M. Dieninger | ||
|Chronic hematologic malignancies | |||
| | | | ||
|-- | |||
|30-Apr | |||
|Class participants | |||
|Journal (Fleming) | |||
| | | | ||
|-- | |-- | ||
| | |4-May | ||
| | |K. Nazemi | ||
| | |Pediatric brain cancer | ||
| | | | ||
|-- | |-- | ||
| | |6-May | ||
| | |J. Alumkai | ||
|Prostate | |||
| | | | ||
|-- | |-- | ||
| | |7-May | ||
| | |Class participants | ||
| | |Journal (Nazemi - time TBA) | ||
| | | | ||
|-- | |-- | ||
| | |11-May | ||
| | |A. Blauvelt | ||
| | |Skin cancer | ||
| | | | ||
|-- | |-- | ||
| | |13-May | ||
| | |S. Chui | ||
|Breast cancer | |||
| | | | ||
|-- | |-- | ||
| | |14-May | ||
|SRF | |||
|class cancelled | |||
| | |||
| | |||
| | | | ||
|-- | |-- | ||
Revision as of 12:16, 30 March 2009
Home Faculty Graduate Program Postdocs OHSU Knight Core Facilities
Programs
Res Group Meetings
Cancer Journal Club
Cell/CANB 616
Gen. Inst/R3 Club
CANB 610
Objectives of the Advanced Topics in Cancer Biology class (CELL 616)
This upper level course will provide clinical insight into cancer research. We have designed this course to address mechanism and current therapeutic options for cancer treatment in the first part of the course. The second part of the course is designed to examine the current state of clinical diagnoses and treatment of different types of cancers that afflict different organ systems. These lectures are designed to address the state of the art and to provide insight into where the field is moving in the future. The overall goal of this course is to provide the current state of the field from a clinical standpoint in anticipation that this knowledge will then be applied to guiding important findings in basic research.
Logistics
- When and where we meet
- RJH 5501
- The class will run every Spring term
- Mon, Wed: 1:30-3:00 PM; Thurs: 1:30-2:30 PM
- Mon, Wed class is one hour lecture followed by discussion, Thurs class is presentation of a relevant journal article
- Organizer contact information: searsrATohsu.edu, wongmeATohsu.edu
Participants, Expectations and Grading
- The class is open for registration to all second year and above students. The class is also open to postdoctoral fellows for informal auditing. Please contact the organizers with any questions regarding participation.
- Participants are required to attend at least one tumor board meeting of their choice:
- 1. Gastrointestinal Tumor Board, 7AM, Thursday, Hatfield 14D03(occasionally is canceled)
- 2. Breast Tumor Board, 8:30AM, Thursday, Hatfield 14D03
- 3. Hem/Onc Tumor Board, 8AM, Wednesday, Hatfield 14D03, Lymphoma, leukemia alternate every other week
- (occasionally not held if an outside speaker is scheduled)
- 4. Sarcoma tumor board, 12:30-1:30 PM, Wednesday, Hatfield 14D03(except for the 4th Wednesday of each month)
- Each participant will present a tumor board presentation as follows:
- 20 minutes in length, powerpoint presentation format, include:
- 1. Background (cancer type, stage, grade, what is known about this cancer)
- 2. Known molecular pathways underlying the disease and any potential therapeutic treatments
- 3. Present the issues discussed related to the individual patient you will be discussing
- 4. What was the course of actions? And follow-up? Prognosis?
- 5. Your insights or interests pertaining to this case.
- For students, your grade will be based upon three criteria:
- 1. Class participation (30%)
- (Your journal presentation participation and how interactive you are during the lecture)
- 2. Your tumor board presentation (30%)
- 3. Final Exam (40%)
- (This exam is a written review of one cancer type (your choice))
- Within this review you will include information addressing: background on this type of cancer, demographics, current therapies, known molecular mechanisms, molecular :and animal models that exist, cutting edge research being performed to elucidate the underlying molecular pathway and/or development of novel therapeutics.
Student and Potdoctoral Participants
Schedule
| Date | Presenters | Topic | Links & attachments |
| 30-Mar | M. Turker | Mutagenic mechanisms | |
| 1-Apr | M. Kulesz-Martin | Clinical carcinogenesis | |
| 2-Apr | Class participants | Journal (Turker) | |
| 6-Apr | R. Sears | Metastasis and angiogenesis | |
| 8-Apr | M. Troxel | Solid cancer pathology | |
| 9-Apr | Class participants | Journal (Troxel) | |
| 13-Apr | C. Lopez | Targeted Cancer Therapeutics | |
| 15-Apr | B. Fox | Immunotherapy | |
| 16-Apr | Class participants | Journal (J. Gallegos) | |
| 20-Apr | C. Okada | Hematology pathology | |
| 22-Apr | M. Wong | Cancer stem cells | |
| 23-Apr | Class participants | Journal (Wong) | |
| 27-Apr | W. Fleming | Acute hematologic malignancies | |
| 29-Apr | M. Dieninger | Chronic hematologic malignancies | |
| 30-Apr | Class participants | Journal (Fleming) | |
| 4-May | K. Nazemi | Pediatric brain cancer | |
| 6-May | J. Alumkai | Prostate | |
| 7-May | Class participants | Journal (Nazemi - time TBA) | |
| 11-May | A. Blauvelt | Skin cancer | |
| 13-May | S. Chui | Breast cancer | |
| 14-May | SRF | class cancelled | |
| 04/02/2009 | Vince Bicocca | ||
| 04/09/2009 | Vivain Wu | ||
| 04/16/2009 | David Qian | ||
| 04/23/2009 | Yun Yin Lim | ||
| 04/30/2009 | Ali Macleod | ||
| 05/14/2009 | Jayme Gallegos | ||
| 05/21/2009 | Aaron Wortham | ||
| 05/28/2009 | Arun Kumar | ||
| 06/04/2009 | Ashley Kamimae-Lanning | ||
| 06/11/2009 | Charlie Lopez |
